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Abstract
Purpose This study aims to verify if luteal estradiol pre-
treatment improves IVF/ICSI outcomes in a GnRH antag-
onist protocol as compared with a micro dose GnRH
agonist protocol in poor-responding patients.
Methods A total of 116 IVF/ICSI cycles were included in
this prospective randomized single blind clinical trial. The
selected women were randomly assigned to receive an
estradiol pre-treatment in a GnRH antagonist protocol
(daily oral Estradiol Valerate 4 mg preceding the IVF cycle
from the 21st day until the first day of the next cycle) or in
oral contraceptive pill micro dose GnRH agonist protocol.
Results The patients in the luteal estradiol protocol
required more days of stimulation (10.9 ± 1.6 vs. 10.2 ±
1.8) and a greater gonadotropin requirement (3,247.8 ±
634.6 vs. 2,994.8 ± 611 IU), yet similar numbers of
oocytes were retrieved and fertilized. There was no
significant difference between the two groups in terms of
the implantation rates (9.8 vs. 7.9 %) and the clinical
pregnancy rates per transfer (16.3 vs. 15.6 %).
Conclusion This study demonstrates that the use of
estradiol during a preceding luteal phase in a GnRH
antagonist protocol can provide similar IVF outcomes
when compared to a micro dose GnRH agonist protocol.
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Introduction
Some women undergoing infertility treatments respond
poorly to the usual gonadotropin stimulation protocol [1].
In spite of significant advances in assisted reproductive
techniques (ART), the management of poor-responding
patients is still intricate [2]. A poor ovarian response to
controlled ovarian hyper stimulation (COH) occurs in
9–24 % of women undergoing IVF [1, 3, 4]. Although
there is lack of uniform definitions, poor response to
controlled ovarian hyper stimulation can be defined as
insufficient ovarian response in terms of low number of
follicles developed, low serum E2 levels, and low number
of oocytes retrieved in spite of adequate ovarian stimula-
tion [1, 4]. Poor-response patients, following a standard
ovarian stimulation protocol, have lower pregnancy rates
compared with normal responders [1].
So far, several strategies have been recommended for
poor responders. The most frequently used ovarian stimu-
lation protocols are beginning of gonadotropin and a GnRH
agonist (GnRH-a) together in the follicular phase (the so-
called micro dose flare protocol) and the GnRH antagonist
regimens [3]. A micro dose protocol has the benefit of the
initial rise in endogenous gonadotropin and maintains
effectiveness in premature luteinizing hormone (LH) surge
prevention. Pretreatment with oral contraceptives prevents
corpus luteum formation and the following stimulation
from exogenous GnRH-a [5].
GnRH antagonists are interesting because their begin-
ning occurs after the start of gonadotropin stimulation, thus
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minimizing their impact on early follicular recruitment. [6].
An approach for treating poor responders is to give E2 in
the luteal phase before IVF hyper stimulation [7–9].
Endogenous FSH in the previous luteal phase may
selectively stimulate larger follicles and consequently lead
to a size inconsistency in the developing follicles. This size
inconsistency may cause fewer follicles to be responsive to
gonadotropin stimulation [10]. Fanchin et al. [8] found that
luteal phase E2 resulted in a greater number of follicles
C16 mm, further mature oocytes, and more accessible
embryos when compared with a control group.
Thus, the purpose of the present study is to compare the
results gained from the stimulation of patients who had
anticipated poor ovarian responses and got a luteal phase
estradiol pre-treatment in a GnRH antagonist protocol with
the results gained from the stimulation of those who
underwent in a micro dose agonist flare protocol.
Materials and methods
Study design
This prospective randomized single blind clinical trial
included 116 women with poor ovarian responses, who
underwent COH for IVF in Yazd Research and Clinical
Center for Infertility affiliated to Shahid Sadoughi Uni-
versity of Medical Sciences from March 2011 to March
2012. The study was approved by the ethics committee of
Yazd Research and Clinical Center for Infertility. Ran-
domized assignment of the two treatments was performed
by a computer-based program. Before starting the study,
informed consent was obtained from each couples. The
inclusion criteria were a history of poor response in a prior
cycle (B3 oocytes retrieved, poor-quality oocytes, or cycle
cancelation due to inadequate ovarian response), or women
anticipated to be a poor responder based on initial testing
(third-day FSH level of 10 mIU/mL, or a basal antral fol-
licle count \5). The exclusion criteria were stage III–IV
endometriosis, autoimmune or chromosomal disorders,
endocrine or metabolic diseases, or existence of only one
ovary. Patients exhibiting a day 3 serum FSH level greater
than 15 mIU/mL were excluded. Sever male factor
(patients with azoospermia and normal morphology of
sperm \4 %) and patients with hydrosalpinx also were
excluded from the study.
Treatment protocols
Fifty eight randomly selected women underwent IVF using
the E2/antagonist protocol (E2/ANT group). In this group,
estradiol (Aburaihan Pharmaceutical Co., Tehran, Iran)
2 mg was started orally twice a day on the 21st luteal day
and continued until menstruation. Once menses began,
estradiol was discontinued and gonadotropin stimulation
was started on the 2nd day of the menstrual cycle. Gonal-F
(Gonal-F, Serono, Italy) at 225–300 IU/day was initiated
from the second day of menses and was adjusted according
to serum E2 concentrations and the ovarian response as
noted by ultrasound. When the leading follicle reached
14 mm in diameter, Cetrorelix (Merck-Serono Germany)
0.25 mg SC was added and continued every day until and
including the day of hCG administration. Another group
consisted of 58 women who underwent ovarian stimulation
for IVF using micro dose agonist protocol (micro dose
group). In these patients, low-dose OCP (30 mcg Ethinyl
Estradiol and 0.3 mg Norgestrel, Aburaihan Pharmaceuti-
cal Co., Tehran, Iran) was started on the 2nd day of the
previous cycle for 21 days. On the second day of men-
struation, Suprefact (Buserelin acetate, Aventis Pharma
Deutschland, Germany) 50 lg SC was started and contin-
ued twice a day until the day of hCG administration. After
2 days (on the fourth day of menstruation), Gonal-F was
started at 225–300 IU/day. In these patients, like in the
other group, the dose of Gonal-F was adjusted according to
serum E2 concentrations and ovarian responses as noted by
ultrasound.
IVF procedure
In both groups, 10,000 IU of hCG (pregnyl, Daropakhsh,
Iran) was administered IM when at least two follicles
reached C18 mm in diameter. The follicles were followed
36 h later by ultrasound-guided transvaginal oocyte
retrieval. Follicles C14 mm aspirated and the physicians
performing the follicular aspiration blinded to the stimu-
lation protocol. The IVF and intracytoplasmic sperm
injection (ICSI) procedures were performed, and the
embryos were transferred on the third day after retrieval
with a Labotect catheter (Labotect, Gotting, Germany). A
good-quality embryo was defined as seven or more blas-
tomeres on day 3, equally sized blastomeres, and \20 %
fragmentation and poor-quality embryos consist of all the
rest. The number of transferred embryos depended on the
embryo quality and the patient’s age. All the patients
received 100 mg of progesterone (Aburaihan Pharmaceu-
tical Co., Tehran, Iran) IM per day for luteal support, which
was initiated on the day of oocyte retrieval. Serum B-hCG
was checked 14 days after the embryo transfer. If the
patient was pregnant, then progesterone was continued
until the 10th week of pregnancy. Chemical pregnancy was
defined as serum B-hCG [50 IU/L after 14 days from
embryo transfer. Clinical pregnancy was defined as the
presence of a gestational sac with heart beat identified by
ultrasound 5 weeks after the embryo transfer. The
implantation rate was defined as the ratio of gestational
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sacs to the number of embryos transferred and Clinical
abortion rate was determined as clinically recognized
pregnancy losses before 20 weeks of gestation. Criteria for
cycle cancelation due to poor ovarian response included the
presence of fewer than two growing follicles on ultrasound’
with an E2 level \200 pg/ml on day 7 of stimulation.
Outcome measures and statistical analysis
The primary outcome measures included the clinical
pregnancy rates and the number of oocytes retrieved. The
secondary outcome measures included the cycle length,
the total dose of gonadotropin, and the implantation rate.
The SPSS 19 package program was used to perform all the
statistical analyses. v2-test, Fisher’s exact test, Mann–
Whitney test, and Independent sample t test were used
when appropriate. P \ 0.05 was considered statistically
significant. The data are presented as the mean ± standard
deviation unless otherwise indicated.
Results
116 patients were enrolled in this study, and none of them
was lost to follow up; therefore, final analysis was done on
58 patients in each group. Of the 116 poor-responding
patients included in this study, 58 were treated with a micro
dose protocol (MD), and 58 received estradiol pre-treat-
ment with an antagonist protocol (E2/ANT). 12 women in
E2/ANT group did not transfer embryo: three patients
because of poor ovarian response, five patients because of
failed oocyte retrieval, and four because of failed fertil-
ization. In MD group, 15 women did not transfer embryo:
two patients because of poor ovarian response,six patients
because of failed oocyte retrieval, and seven because of
failed fertilization. However, they were included in the
final analysis. Table 1 presents the patients’ characteristics
in the two groups. The demographic parameters were
similar in both groups, including age, basal FSH level, the
number of previous cycles, etiology of infertility, and
infertility duration. Table 2 compares the cycle character-
istics in the two groups. The patients undergoing stimula-
tion with E2/ANT had a significantly greater requirement
for gonadotropin (3,247.8 ± 634.6 vs. 2,994.8 ± 611 IU;
P = 0.03). As compared with MD group, they achieved a
similar number of oocytes retrieved and the number of
mature oocytes as well. The endometrial thickness and the
estradiol concentration were similar between the two
groups on the day of hCG. However, the days of stimula-
tion in E2/ANT group were 10.9 ± 1.6 vs. 10.2 ±
1.8 days in MD group (P = 0.04). The embryo data and
the clinical outcome of the study groups are compared in
Table 3. The number of embryos obtained and transferred
and the number of good-quality embryos were not different
in the two groups. In addition, no significant differences
were noted in the implantation rate (9.8 vs. 7.9 %;
P = 0.36), clinical pregnancy rate per cycle (13.8 vs.
12.1 %; P = 0.78), and clinical pregnancy rate per transfer
(16.3 vs. 15.6 %; P = 0.91). Also there was no difference
between the two groups with regard to fertilization rate
(59.7 vs. 49.6 %; P = 0.13) and clinical abortion rate (12.5
vs. 14.3 %; P = 0.91). The percentage of conventional
IVF and ICSI was similar in two groups. The total can-
celation rate was not significantly different between
groups. (20.7 vs. 25.8 %; P = 0.66).
Table 1 Patients characteristics
Characteristics E2/ANT MD P value
n = 58 n = 58
Age (years) 32.9 ± 6.3 33.3 ± 5.5 0.72
Basal FSH (IU/L) 7.4 ± 2.0 7.8 ± 1.8 0.22
Duration of infertility (years) 7.8 ± 5.7 8.2 ± 5.1 0.43
No. of prior attempted cycles 1.5 ± 0.6 1.4 ± 0.4 0.67
Etiology of infertility no (%) 0.84
Male factor 31 (53.4) 29 (50)
Tubal factor 6 (10.4) 8 (13.8)
Unexplained 16 (27.6) 14 (24.1)
Mild endometriosis 5 (8.6) 7 (12.1)
Student t test, Mann–Whitney test and Chi-square test. PV\0.05 was
significant
ANT gonadotropin-releasing hormone antagonist, E2 estradiol, MD
micro dose
Table 2 Cycle characteristics of the study groups
Characteristics E2/ANT MD P value
n = 58 n = 58
No. of follicles
[16 mm
6.1 ± 2.0 5.7 ± 2.5 0.31
No. of oocytes
retrieved
4.2 ± 3.0 3.9 ± 2.9 0.66
No. of mature
oocytes
3.5 ± 2.2 3.4 ± 2.4 0.88
Days of stimulation 10.9 ± 1.6 10.2 ± 1.8 0.04
Endometrial
thickness on day of
hCG (mm)
9.3 ± 1.4 8.9 ± 1.5 0.16
Peak E2 on day of
hCG (pg/ml)
958.1 ± 538.7 943.1 ± 563.4 0.53
Total dose of
gonadotropin (IU)
3,247.8 ± 634.6 2,994.8 ± 611 0.03
ANT gonadotropin-releasing hormone antagonist, E2 estradiol, MD
micro dose. Mann–Whitney test and student t test. PV \0.05 was
significant
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Discussion
The definition of poor-responding patients is controversial
in the literature [11]. The best stimulation protocol for poor
responders should have an appropriate rate of cycle can-
celation, provide the maximum number of mature oocytes,
and have maximal pregnancy and delivery rates [3].
Quite recently, a better understanding of follicular
development has resulted in the improvement of strategies
for ovarian stimulation in poor-responding patients. It has
been found that during the luteal-follicular transition, FSH
protects early antral follicles from atresia and causes their
growth [12]. Larger follicles are more sensitive to FSH
and, therefore, begin to respond and develop during the late
luteal phase [7, 9, 13, 14]. Thus, asynchronous follicular
growth during controlled ovarian hyper stimulation may be
an outcome of the size heterogeneities of early antral fol-
licles during the early follicular phase [7].
Thus, this study investigated the effect of exogenously
administered estradiol in the preceding luteal phase in a
GnRH antagonist protocol on IVF parameters and com-
pared to a micro dose GnRH agonist protocol in poor-
responding patients. The results of this study showed no
significant differences between the two groups in the mean
number of oocytes, mature oocytes, fertilization, implan-
tation, and clinical pregnancy rates. Compared with the
micro dose group, the patients who were receiving luteal
phase estradiol experienced an increase in the total dose of
gonadotropin used as well as the days of stimulation. A
probable explanation for the increased use of gonadotropin
is that the inhibitory effect of estradiol on FSH in the luteal
phase resulted in slower growth of the follicles once
stimulation started.
This study’s findings are consistent with the published
literature in many regards. In a retrospective paired study
by Frattarelli et al., the total dose of gonadotropin used
would be increased in the luteal estradiol group. However,
according to their study, giving estradiol in the luteal phase
before gonadotropin stimulation seems to increase the
number and the quality of embryos achieved in poor
responders [15].
Weitzman et al. reported that the use of E2 patch and a
GnRH antagonist during a former luteal phase in patients
with a history of poor response could offer similar IVF
outcomes when compared with the micro dose GnRH
agonist protocol. They found no differences in oocyte
outcome, cancelation rates, or pregnancy rates between the
groups. Their findings supported the use of both protocols
as viable options for poor responders [11].
Dragisic et al. used a luteal E2 patch combined with a
GnRH antagonist in the luteal phase before starting gona-
dotropin stimulation in a GnRH antagonist protocol. They
showed better outcomes, as compared to outcomes in
previous cycles, for patients undergoing stimulation with
the luteal E2 patch/GnRH antagonist protocol [16]. The
results of their study are consistent with those of Frattarelli
et al. with regard to an improved number of oocytes
retrieved. However, Frattarelli et al. did not find an
increase in fertilization rate. The medication type and route
of administration vary among studies. Frattarelli et al. used
oral estradiol, as Dragisic et al. used an estradiol patch for
administration medication.
Shastri et al. compared the in vitro fertilization (IVF)
results for young poor responders treated in a luteal
estradiol/gonadotropin-releasing hormone antagonist pro-
tocol with the results of a micro dose protocol. The patients
in the E2/antagonist group had a greater gonadotropin
necessity and a lower E2 level. However, the number of
oocytes retrieved and fertilized was similar in the two
groups. The E2/antagonist group showed to be tending
toward improved implantation rates and ongoing preg-
nancy rates per started cycle [17].
In a retrospective cohort study, Elassar et al. [18]
showed that the coordination of follicular growth in the
luteal phase is no better by using E2 and a GnRH antag-
onist than E2 alone in poor responders.
Based on Hill et al.’s study, giving E2 in the luteal phase
before gonadotropin stimulation is associated with an
increase in the dose of gonadotropin required, the peak E2
levels, and the percentage of embryos reaching the C7-cell
Table 3 Embryo data and clinical outcome of the study group
Characteristics E2/ANT MD P value
n = 58 n = 58
No. of embryos obtained 2.2 ± 1.8 2.0 ± 1.9 0.23
No. of embryos transferred 1.6 ± 1.0 1.4 ± 1.2 0.26
Transfers with good quality
embryos
53.4 % 47.4 % 0.36
Fertilization rate 59.7 % 49.6 % 0.13
Fertilization procedures (%) 0.30
IVF 34.5 % 24.1 %
ICSI 65.5 % 75.9 %
Total cancelation rate n (%) 0.66
Poor ovarian response 3 (5.2 %) 2 (3.4 %)
Failed oocyte retrieval 5 (8.6 %) 6
(10.3 %)
Failed fertilization 4 (6.9 %) 7
(12.1 %)
Implantation rate 9.8 % 7.9 % 0.36
Clinical pregnancy rate/cycle 13.8 % 12.1 % 0.78
Clinical pregnancy rate/transfer 16.3 % 15.6 % 0.91
Clinical abortion rate 12.5 % 14.3 % 0.91
ANT gonadotropin-releasing hormone antagonist, E2 estradiol, MD
micro dose. Mann–Whitney test and Chi-square test. PV \0.05 was
significant
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stage in patients who are poor responders during IVF.
Luteal E2 was associated with improved embryo devel-
opment and a trend toward improved delivery rate. Con-
sistent with other studies, the luteal E2 protocol required a
higher dose of gonadotropin with longer stimulation [10].
Ye et al. randomly assigned normal responders to either
standard long GnRH agonist protocol or luteal E2 before
GnRH antagonist cycles. They reported that the luteal E2
pre-treatment before GnRH antagonist protocol signifi-
cantly increases serum LH level and incidence rate of
premature LH. However, compared with long GnRH ago-
nist protocol, no significant effect is observed on implan-
tation, clinical pregnancy, live birth, and early pregnancy
loss rates [19].
According to the results of this study, neither of the two
treatment regimens had major priority over the other. In
conclusion, this study demonstrates that the use of estradiol
during the preceding luteal phase in a GnRH antagonist
protocol can bring about similar IVF outcomes when
compared with a micro dose GnRH agonist protocol.
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